ACERUS OTC Stock Volatility

ASPCF -  USA Stock  

USD 0.03  0.0018  6.38%

ACERUS PHARMACEUTICALS appears to be out of control, given 3 months investment horizon. ACERUS PHARMACEUTICALS secures Sharpe Ratio (or Efficiency) of 0.0308, which signifies that the company had 0.0308% of return per unit of risk over the last 3 months. Our approach to foreseeing the volatility of a stock is to use all available market data together with stock-specific technical indicators that cannot be diversified away. We have found twenty-one technical indicators for ACERUS PHARMACEUTICALS CORP, which you can use to evaluate the future volatility of the entity. Please makes use of ACERUS PHARMACEUTICALS's mean deviation of 6.4, and Coefficient Of Variation of 6097.0 to double-check if our risk estimates are consistent with your expectations.

ACERUS Volatility 

 
Refresh
ACERUS PHARMACEUTICALS OTC Stock volatility depicts how high the prices fluctuate around the mean (or its average) price. In other words, it is a statistical measure of the distribution of ACERUS daily returns, and it is calculated using variance and standard deviation. We also use ACERUS's beta, its sensitivity to the market, as well as its odds of financial distress to provide a more practical estimation of ACERUS PHARMACEUTICALS volatility.

720 Days Market Risk

Out of control

Chance of Distress

Quite High

720 Days Economic Sensitivity

Responds to the market

ACERUS PHARMACEUTICALS Market Sensitivity And Downside Risk

ACERUS PHARMACEUTICALS's beta coefficient measures the volatility of ACERUS otc stock compared to the systematic risk of the entire stock market represented by your selected benchmark. In mathematical terms, beta represents the slope of the line through a regression of data points where each of these points represents ACERUS otc stock's returns against your selected market. In other words, ACERUS PHARMACEUTICALS's beta of 1.29 provides an investor with an approximation of how much risk ACERUS PHARMACEUTICALS otc stock can potentially add to one of your existing portfolios.
Let's try to break down what ACERUS's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ACERUS PHARMACEUTICALS will likely underperform.
3 Months Beta |Analyze ACERUS PHARMACEUTICALS Demand Trend
Check current 90 days ACERUS PHARMACEUTICALS correlation with market (DOW)

ACERUS Beta

    
  1.29  
ACERUS standard deviation measures the daily dispersion of prices over your selected time horizon relative to its mean. Typical volatile equity has a high standard deviation, while the deviation of a stable instrument is usually low. As a downside, the standard deviation calculates all uncertainty as risk, even when it is in your favor, such as above-average returns.

Standard Deviation

    
  11.36  
It is essential to understand the difference between upside risk (as represented by ACERUS PHARMACEUTICALS's standard deviation) and the downside risk, which can be measured by semi-deviation or downside deviation of ACERUS PHARMACEUTICALS stock's daily returns or price. Since the actual investment returns on holding a position in ACERUS PHARMACEUTICALS stock tend to have a non-normal distribution, there will be different probabilities for losses than for gains. The likelihood of losses is reflected in the downside risk of an investment in ACERUS PHARMACEUTICALS.

ACERUS PHARMACEUTICALS OTC Stock Volatility Analysis

Transformation
The output start index for this execution was zero with a total number of output elements of sixty-one. The Median Price line plots median indexes of ACERUS PHARMACEUTICALS price series. View also all equity analysis or get more info about median price price transform indicator.

ACERUS PHARMACEUTICALS Projected Return Density Against Market

Assuming the 90 days horizon the otc stock has the beta coefficient of 1.289 . This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, ACERUS PHARMACEUTICALS will likely underperform.
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to ACERUS PHARMACEUTICALS or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that ACERUS PHARMACEUTICALS stock's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a ACERUS stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
The company has an alpha of 0.1665, implying that it can generate a 0.17 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Predicted Return Density 
      Returns 

ACERUS PHARMACEUTICALS OTC Stock Risk Measures

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to ACERUS PHARMACEUTICALS or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that ACERUS PHARMACEUTICALS stock's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a ACERUS stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
Assuming the 90 days horizon the coefficient of variation of ACERUS PHARMACEUTICALS is 3246.27. The daily returns are distributed with a variance of 128.95 and standard deviation of 11.36. The mean deviation of ACERUS PHARMACEUTICALS CORP is currently at 6.48. For similar time horizon, the selected benchmark (DOW) has volatility of 0.79
α
Alpha over DOW
0.17
β
Beta against DOW1.29
σ
Overall volatility
11.36
Ir
Information ratio 0.015

ACERUS PHARMACEUTICALS OTC Stock Return Volatility

ACERUS PHARMACEUTICALS historical daily return volatility represents how much ACERUS PHARMACEUTICALS stock's price daily returns swing around its mean daily price change - it is a statistical measure of its dispersion of returns. The firm shows 11.3554% volatility of returns over 90 . By contrast, DOW inherits 0.7407% risk (volatility on return distribution) over the 90 days horizon.
 Performance (%) 
      Timeline 

About ACERUS PHARMACEUTICALS Volatility

Volatility is a rate at which the price of ACERUS PHARMACEUTICALS or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of ACERUS PHARMACEUTICALS may increase or decrease. In other words, similar to ACERUS's beta indicator, it measures the risk of ACERUS PHARMACEUTICALS and helps estimate the fluctuations that may happen in a short period of time. So if prices of ACERUS PHARMACEUTICALS fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility.
Please read more on our technical analysis page.
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for mens and womens health. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada. ACERUS PHARMACEUTICALS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 10 people.

ACERUS PHARMACEUTICALS Investment Opportunity

ACERUS PHARMACEUTICALS CORP has a volatility of 11.36 and is 15.35 times more volatile than DOW. 96  of all equities and portfolios are less risky than ACERUS PHARMACEUTICALS. Compared to the overall equity markets, volatility of historical daily returns of ACERUS PHARMACEUTICALS CORP is higher than 96 () of all global equities and portfolios over the last 90 days. Use ACERUS PHARMACEUTICALS CORP to enhance returns of your portfolios. The otc stock experiences a very speculative upward sentiment. The trend is possibly hyped up. Check odds of ACERUS PHARMACEUTICALS to be traded at $0.0375 in 90 days. . Let's try to break down what ACERUS's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ACERUS PHARMACEUTICALS will likely underperform.

Significant diversification

The correlation between ACERUS PHARMACEUTICALS CORP and DJI is Significant diversification for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding ACERUS PHARMACEUTICALS CORP and DJI in the same portfolio assuming nothing else is changed.

ACERUS PHARMACEUTICALS Additional Risk Indicators

The analysis of ACERUS PHARMACEUTICALS's secondary risk indicators is one of the essential steps in making a buy or sell decision. The process involves identifying the amount of risk involved in ACERUS PHARMACEUTICALS's investment and either accepting that risk or mitigating it. Along with some common measures of ACERUS PHARMACEUTICALS stock risk such as standard deviation, beta, or value at risk, we also provide a set of secondary indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
Risk Adjusted Performance0.0222
Market Risk Adjusted Performance0.1455
Mean Deviation6.4
Semi Deviation9.14
Downside Deviation15.67
Coefficient Of Variation6097.0
Standard Deviation11.26
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential stock investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.

ACERUS PHARMACEUTICALS Suggested Diversification Pairs

Pair trading is one of the very effective strategies used by professional day traders and hedge funds capitalizing on short-time and mid-term market inefficiencies. The approach is based on the fact that the ratio of prices of two correlating shares is long-term stable and oscillates around the average value. If the correlation ratio comes outside the common area, you can speculate with a high success rate that the ratio will return to the mean value and collect a profit.
Visa vs. ACERUS PHARMACEUTICALS
Vmware vs. ACERUS PHARMACEUTICALS
Realty Income vs. ACERUS PHARMACEUTICALS
Sentinelone Inc vs. ACERUS PHARMACEUTICALS
Walker Dunlop vs. ACERUS PHARMACEUTICALS
Citigroup vs. ACERUS PHARMACEUTICALS
Facebook vs. ACERUS PHARMACEUTICALS
Square vs. ACERUS PHARMACEUTICALS
Upstart Holdings vs. ACERUS PHARMACEUTICALS
Main Street vs. ACERUS PHARMACEUTICALS
Flowers Foods vs. ACERUS PHARMACEUTICALS
The effect of pair diversification on risk is to reduce it, but we should note this doesn't apply to all risk types. When we trade pairs against ACERUS PHARMACEUTICALS as a counterpart, there is always some inherent risk that will never be diversified away no matter what. This volatility limits the effect of tactical diversification using pair trading. ACERUS PHARMACEUTICALS's systematic risk is the inherent uncertainty of the entire market, and therefore cannot be mitigated even by pair-trading it against the equity that is not highly correlated to it. On the other hand, ACERUS PHARMACEUTICALS's unsystematic risk describes the types of risk that we can protect against, at least to some degree, by selecting a matching pair that is not perfectly correlated to ACERUS PHARMACEUTICALS CORP.
Please continue to Trending Equities. Note that the ACERUS PHARMACEUTICALS information on this page should be used as a complementary analysis to other ACERUS PHARMACEUTICALS's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Complementary Tools for ACERUS OTC Stock analysis

When running ACERUS PHARMACEUTICALS price analysis, check to measure ACERUS PHARMACEUTICALS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACERUS PHARMACEUTICALS is operating at the current time. Most of ACERUS PHARMACEUTICALS's value examination focuses on studying past and present price action to predict the probability of ACERUS PHARMACEUTICALS's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move ACERUS PHARMACEUTICALS's price. Additionally, you may evaluate how the addition of ACERUS PHARMACEUTICALS to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
The market value of ACERUS PHARMACEUTICALS is measured differently than its book value, which is the value of ACERUS that is recorded on the company's balance sheet. Investors also form their own opinion of ACERUS PHARMACEUTICALS's value that differs from its market value or its book value, called intrinsic value, which is ACERUS PHARMACEUTICALS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACERUS PHARMACEUTICALS's market value can be influenced by many factors that don't directly affect ACERUS PHARMACEUTICALS underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACERUS PHARMACEUTICALS's value and its price as these two are different measures arrived at by different means. Investors typically determine ACERUS PHARMACEUTICALS value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACERUS PHARMACEUTICALS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.